Hubei Haoxin Pharmaceutical Co., Ltd
Hubei Haoxin Pharmaceutical integrates R&D and production of Chinese and Western medicines, established in 2003 with $8M capital.
Introduction
Established in February 2003 with an initial registered capital of $8 million, Hubei Haoxin Pharmaceutical Co., Ltd. is a successful Sino-Hong Kong joint venture. This enterprise specializes in the research, development, and manufacturing of both original Chinese and Western medicine preparations, as well as pharmaceutical intermediates. Over the years, the company has produced a range of important drugs, including Erythromycin Huyi, Epistine Hydrochloride, Amisulpride, Irinotecan Hydrochloride, Anhydrous Paclitaxel, Dasatinib, Temozolomide, and Granisetron Hydrochloride.
Information
Categories
More Websites
Brief: A global company providing high-quality, cost-effective solutions for oil, gas, refining, chemical, and power industries.